Editorial

Determinants and Targets in Progressive Airways Disease☆

The organisers (Associate Professor John Wilson, Respiratory Medicine, Alfred Hospital; Dr Gary Anderson, Associate Professor Alastair Stewart, Department of Pharmacology, University of Melbourne) are grateful for unrestricted educational grants for Glaxo Wellcome (Australia) and Novartis (U.K.)